Dry alginate beads for fecal microbiota transplantation: From model strains to fecal samples.

Alginate Bacteria formulation Bacterial viability Fecal microbiota transplantation Gut microbiome Microencapsulation

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 May 2023
Historique:
received: 07 03 2023
revised: 05 04 2023
accepted: 11 04 2023
medline: 12 5 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Clostridioides difficile infection (CDI) is a critical nosocomial infection with more than 124,000 cases per year in Europe and a mortality rate of 15-17 %. The standard of care (SoC) is antibiotic treatment. Unfortunately, the relapse rate is high (∼35 %) and SoC is significantly less effective against recurrent infection (rCDI). Fecal microbiota transplantation (FMT) is a recommended treatment against rCDI from the second recurrence episode and has an efficacy of 90 %. The formulation of diluted donor stool deserves innovation because its actual administration routes deserve optimization (naso-duodenal/jejunal tubes, colonoscopy, enema or several voluminous oral capsules). Encapsulation of model bacteria strains in gel beads were first investigated. Then, the encapsulation method was applied to diluted stools. Robust spherical gel beads were obtained. The mean particle size was around 2 mm. A high loading of viable microorganisms was obtained for model strains and fecal samples. For plate-counting, values ranged from 10

Identifiants

pubmed: 37075927
pii: S0378-5173(23)00381-2
doi: 10.1016/j.ijpharm.2023.122961
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122961

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: co-author is a member of the editorial board of IJP - Eric Allémann.

Auteurs

Adèle Rakotonirina (A)

School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.

Tatiana Galperine (T)

Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, 1011 & 1015 Lausanne, Switzerland; French Group of Faecal Microbiota Transplantation, Paris, France.

Maxime Audry (M)

Service of Pharmacy, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Marie Kroemer (M)

Service of Pharmacy, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Aurélie Baliff (A)

Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, 1011 & 1015 Lausanne, Switzerland.

Laurent Carrez (L)

Service of Pharmacy, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Farshid Sadeghipour (F)

School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland; Service of Pharmacy, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Jacques Schrenzel (J)

Genomic Research Lab, Service of Infectious Diseases, Geneva University Hospitals and University of Geneva, 1211 Geneva, Switzerland.

Benoît Guery (B)

Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, 1011 & 1015 Lausanne, Switzerland.

Eric Allémann (E)

School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland. Electronic address: eric.allemann@unige.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH